TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Type 2 Diabetes diagnosis~* Plan to fast during Ramadan~* Treated with a combination of metformin and an Sulfonylurea (SU) for at least 12 weeks and HbA1c ≤8.5% at Visit 1~* Taking a sulfonylurea treatment for less than 3 years prior to Visit 1~* Body mass index (BMI) ≥22 and ≤45 kg/m2 at Visit 1~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~* Patients who are taking any other anti-diabetes drug (oral or injection) other than metformin and an SU component.~* Inability to comply with the study procedures or medications.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin + placebo to Gliclazide (Type: EXPERIMENTAL): Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
- Gliclazide + placebo to Vildagliptin (Type: ACTIVE_COMPARATOR): Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nobori Dual Antiplatelet Therapy as Appropriate Duration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects \> 20 years old~* Undergoing percutaneous intervention with Nobori deployment~* No contraindication to prolonged DAPT~Exclusion Criteria:~* Subjects absolutely necessitating continuous DAPT~* Planned surgery necessitating discontinuation of antiplatelet therapy after enrollment.~* Active pathological bleeding~* Status of cardiogenic shock at enrollment~* Pregnant women~* Life expectancy of \< 1.5 years~* Subjects unable to give informed consent~* Episode of stroke \< 6 months~* Subjects with allergies or hypersensitivity to material of coating, Biolimus A9, and antiplatelet drugs.~* Subjects treated with other kind of DES or BMS during the index procedure~* Previous intervention with DES \< 6 months.~* Study participation impractical per investigator judgment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Short-term DAPT (6 months) group (Type: EXPERIMENTAL): 6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
- Long-term DAPT (18 months) group (Type: EXPERIMENTAL): 18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult male or female subjects 18 years of age and older, with no past or present history of any significant internal disease~* Subjects who:~  * show a high degree of fluorescence of the facial skin under a Wood's lamp, indicating the presence of P acnes~ * have Baseline P acnes count of \> 10,000 per cm2 CFU of the facial skin (forehead)~ * have high level resistance to erythromycin, variable resistance to clindamycin, resistance to tetracycline and variable resistance to doxycycline and minocycline~Exclusion Criteria:~* Subjects who exhibit any skin disorders of an acute or chronic nature (e.g., psoriasis, eczema, etc)~* Subjects who have taken topical or systemic antibiotics within 4 weeks prior to baseline assessments~* Subjects who have used other medications which may influence skin surface P acnes levels~* Subjects who are unwilling to refrain from using toners, astringents or other drying agents on the face during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Treatment (Type: EXPERIMENTAL): Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Confirmed cancer of the prostate~* Evidence of metastatic disease~* Have a life expectancy greater than 12 weeks~* Have at least 4 weeks from previous major surgery to date of first study agent given~* Have progressive hormone-refractory disease after orchiectomy or gonadotropin-releasing hormone analog and/or antiandrogen treatment within 6 months prior to the first study agent administration Exclusion Criteria~* Have known Central Nervous System metastases (cancerous tumors that have spread to the brain from somewhere else in the body)~* Had prior systemic non-hormonal therapy for hormone refractory prostate cancer~* Have known Human Immunodeficiency Virus (HIV, a life-threatening infection which you can get from an infected person's blood or from having sex with an infected person) seropositivity or known hepatitis B or C infection~* Have planned major surgery during the study~* Have taken any over-the-counter (medicine that can be bought without a prescription) or herbal treatment for prostate cancer within 4 weeks prior to the first study treatment administration

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel + Prednisone + Placebo (Type: ACTIVE_COMPARATOR): Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m\^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
- Docetaxel + Prednisone + Intetumumab (Type: EXPERIMENTAL): Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 20 - 80 years old~* Gender: Male or female~* Status: Outpatients~* Elevated Serum Creatinine~Exclusion Criteria:~* Patients suspected of malignant hypertension~* Patients with a clinically significant allergy~* Patients who have received other investigational drug Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese men and women with type 2 diabetes mellitus that is managed with oral anti-hyperglycemic agent(s).~* Body mass index (BMI) 27 to 45 kg/m2, inclusive.~* Ability to complete a 1 year study~Exclusion Criteria:~* Pregnancy~* Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months prior to screening~* History of symptomatic heart valve disease~* Serious or unstable current or past medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lorcaserin 10 mg QD (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and placebo tablet each evening
- Lorcaserin 10 mg BID (Type: EXPERIMENTAL): Lorcaserin 10 mg tablet each morning and evening
- Matching Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet each morning and evening

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OptiVol® Care Pathway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject (or subject's legally authorized representative) is willing and able to sign and date written consent form and Authorization for Access to and Use of Health Information~* Subject is at least 18 years of age~* Subject is willing and able to comply with Clinical Investigation Plan~* Subject is willing and able to transmit data using Medtronic CareLink® Network~* Subject has market released right atrial (RA) (if applicable), right ventricular (RV), and left ventricular (LV) (if applicable) leads and one of the following generators implanted: Concerto® CRT-D - Model C154DWK, Virtuoso® DR ICD - Model D154AWG, Virtuoso® VR ICD - Model D154VWC, Consulta™ CRT-D - Model D224TRK, Secura™ DR ICD - Model D224DRG, Secura™ VR ICD - Model D224VRC, or any future market released Medtronic generator with wireless telemetry, Cardiac Compass with OptiVol Fluid Status Monitoring, and that is supported by the Medtronic CareLink Network~Exclusion Criteria:~* Subject is enrolled in a concurrent study with the exception of a study approved by the Medtronic Clinical Trial Leader prior to enrollment~* Subject has life expectancy of less than 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monthly Review Arm (Type: EXPERIMENTAL): Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
- Quarterly Review Arm (Type: ACTIVE_COMPARATOR): Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Use of Neostigmine in Sepsis and Septic Shock.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85 years.~* Patients diagnosed with sepsis or septic shock according to Third International Consensus Definitions for Sepsis and Septic Shock mentioned above.~* Patients who have ≥ 2 of the following four criteria plus documented infection:~  1. Fever ≥ 38 °C or hypothermia ≤ 36 °C.~ 2. Tachycardia ≥ 100/min.~ 3. Tachypnea ≥ 20/min or hyperventilation.~ 4. Leukocytosis ≥ 12000/mm3 or leukopenia ≤ 4000/mm3 or ≥ 10% immature neutrophils in the differential count.~Exclusion criteria:~* Known hypersensitivity to choline esterase inhibitors.~* Known absolute contra-indications against choline esterase inhibitors such as, myotonic dystrophy; depolarization block by depolarizing muscle relaxants; intoxication by irreversibly acting cholinesterase inhibitors; closed craniocerebral trauma; obstruction in the gastrointestinal tract (mechanical constipation); obstruction in the urinary tract (mechanical urinary retention)~* Known relative contraindications against choline esterase inhibitors: bronchial asthma; bradycardia; AV-conduction disturbances.~* Having undergone solid organ transplantation.~* Pregnant and lactating women.~* Participation in another clinical trial.~* Presence of primary or concomitant illness, impending death.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Neostigmine group (Type: EXPERIMENTAL): This arm will receive -in addition to standard therapy for sepsis and septic shock-Neostigmine methylsulfate ampoule diluted in normal saline, and administered as continuous infusion for five days. The rate of infusion is 0.2 mg/hr.
- Standard group (Type: PLACEBO_COMPARATOR): This arm will receive the standard therapy for sepsis and septic shock only and followed for five days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent for participating in the study and written standard version of informed consent for cardioversion accepted in Institute of Cardiology, Warsaw, Poland~* Age above 18 and good general condition~* Potassium level over 3.5 mmol/l~* Stable cardio-pulmonary state on enrollment~* In case of unclear history of heart failure or suspicion of impaired left ventricle function echocardiography is indicated prior to enrollment~* A long-term antiarrhythmic drug therapy is allowed~Exclusion Criteria:~* Lack of written informed consent~* Antazoline allergy~* AF related to significant valvular disease~* Clinically significant heart failure or ejection fraction \< 55%~* Diastolic blood pressure (BP) \< 100mmHg~* History of significant bradyarrhythmia not treated with permanent pacemaker~* QT prolongation over 440ms or QTc (Bazett's formula) over population norm~* Tachycardia \> 160'~* Advanced liver or kidney failure~* Acute coronary syndrome, coronary artery by-pass graft, stroke or transient ischemic attack within 30 days before enrollment~* Preexcitation in ECG not treated by radiofrequency ablation of accessory pathway~* Signs and symptoms of ischemia related to AF~* An investigational drug used within 30 days before enrollment~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
- Antazoline (Type: EXPERIMENTAL): Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients displaying abnormal fasted triglycerides (\> 2 g/L \[2.26 mmol/L\] and less than or equal to 10 g/L \[11.29 mmol/L\]) and/or fasted low density lipoprotein cholesterol (LDL-CHO; \> 1.6 g/L \[4.15 mmol/L\])~* Patients on stable HAART with 2 NRTIs + 1 NNRTI or 1 PI for at least 3 months prior to screening, and with plasma viral load \< 400 copies/mL for at least 6 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Truvada (Type: EXPERIMENTAL): Truvada once daily with continuation of the current NNRTI or PI at randomization
- Maintain Baseline Regimen (Type: ACTIVE_COMPARATOR): Maintain baseline regimen
- Delayed Truvada (Type: EXPERIMENTAL): Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
- All Truvada (Type: EXPERIMENTAL): Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic functional constipation according to Rome III criteria~* No stool softeners therapy administered during the 7 days prior to Baseline Visit~* Signature of informed consent from by both parents or legal representative~* Willingness to follow the study schedule~Exclusion Criteria:~* Suspicious or established diagnosis of organic constipation~* Delayed emission of meconium in the term newborn~* Presence of severe inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), toxic megacolon~* Presence/Risk of gastroinstestinal perforation~* Presence/Suspiceous intestinal obstruction of symptomatic stenosis~* (Undeterminated) Abdominal pain~* Hypersensitivity to macrogol (polyethylene glycol) or to one or more product excipients~* Hereditary fructose intolerance~* Known hypersensitivity or allergy to any Promelaxin component~* Presence of any other medical condition that contraindicate the use of Promelaxin® or Macrogol 4000

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- micro-enema with Promelaxin (Type: EXPERIMENTAL): 2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
- Macrogol 4000 (Type: ACTIVE_COMPARATOR): One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients at least 12 years of age~* Male and female; female subjects of childbearing potential must be willing to use birth control~* Pre-bronchodilator FEV1 of 40-90% predicted normal~* Reversibility FEV1 of at least 12% and 200mL~* Current asthma therapy includes inhaled corticosteroid use for at least 12 weeks prior to first visit~Exclusion Criteria:~* History of life-threatening asthma during last 10 years~* Respiratory infection or oral candidiasis~* Asthma exacerbation requiring oral corticosteroids or that required overnight hospitalisation requiring additional asthma treatment~* Uncontrolled disease or clinical abnormality~* Allergies to study drugs or the excipients~* Taking another investigational medication or prohibited medication~* Night shift workers~* Current smokers or subjects with a smoking history of at least 10 pack years

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate/Vilanterol (GW642444) (Type: EXPERIMENTAL): Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
- Fluticasone Furoate (Type: EXPERIMENTAL): Fluticasone furoate inhalation powder once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo inhalation powder once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete